Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal management of HFs requires a personalised approach to identify the treatment with the best benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens. Since isoflavones have oestrogenic properties and it is not known if they can be safely consumed by women with previous hormone-dependent cancer, they were excluded. Selective serotonin reuptake inhibitors/selective serotonin-norepinephrine reuptake inhibitors, as well as other neuroactive agents, some herbal remedies and behavioural strategies are considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445536 | PMC |
| http://dx.doi.org/10.3332/ecancer.2019.909 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Efficacy of Combined Intravaginal Estriol Therapy and Kegel Exercises in Managing Menopausal Atrophic Vulvovaginitis.
Clin Pract
January 2025
Faculty of Medicine, Ovidius University of Constanta, 900470 Constanta, Romania.
: This is a prospective study. Atrophic vulvovaginitis (VVA), a prevalent condition resulting from estrogen deficiency after the menopause, is characterized by symptoms such as vaginal dryness, itching, burning, dyspareunia, and urinary discomfort. Standard treatment involves systemic estrogen replacement therapy (HRT) and localized estrogen treatments, such as estriol.
View Article and Find Full Text PDFSafety Implications of Off-Label Medication Use in Athletes: A Narrative Review.
Medicines (Basel)
November 2024
Polytechnic Institute of Coimbra, Coimbra Health School, Farmácia, 3046-854 Coimbra, Portugal.
In recent years, the off-label use of medications in sports has increased significantly, primarily driven by psychological and social factors. Athletes frequently misuse drugs without adequate medical supervision, relying on unreliable sources of information, which leads to improper usage and serious health risks. This narrative review analyzes literature from PubMed (Medline), Scopus, and Web of Science databases, focusing on studies up to December 2023, to examine the safety concerns related to off-label drug use in sports.
View Article and Find Full Text PDFEndometriotic lesions exhibit distinct metabolic signature compared to paired eutopic endometrium at the single-cell level.
Commun Biol
August 2024
Department of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Article Synopsis
- * Researchers found that these endometriotic lesions use more sugar for energy, which suggests that we might be able to treat the disease without hormones by focusing on how the cells get their energy.
- * They studied different types of cells in both healthy and affected tissue from women with endometriosis and discovered that certain cells change a lot in terms of energy use, pointing to new ways to possibly treat the disease.
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies.
Expert Opin Ther Targets
August 2024
Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA.
Introduction: Uterine fibroids, the most common nonmalignant tumors affecting the female genital tract, are a significant medical challenge. This article focuses on the most recent studies that attempted to identify novel non-hormonal therapeutic targets and strategies in UF therapy.
Areas Covered: This review covers the analysis of the pharmacological and biological mechanisms of the action of natural substances and the role of the microbiome in reference to UFs.
Pre-clinical and early clinical considerations for the development of non-hormonal contraceptives for men.
Andrology
October 2024
Contraception Research Branch, Fertility and Infertility Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Introduction: This manuscript presents non-hormonal male contraceptive development in the context of mitigating risk to investigators and investors.
Objective: The manuscript uses examples to illustrate drug development principles to move a project from discovery to development. The content is intended for those with reproductive biology backgrounds without significant exposure to drug development-particularly early-stage targeted drug development-and those with general interest in developing non-hormonal methods of contraception.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!